News about "GSK"

Ris-Rez Cuts Risk of Death by 54 Percent vs Topotecan in Relapsed SCLC in China

Ris-Rez reduced the risk of death by 54 percent versus topotecan in relapsed SCLC in China, extending median overall survival to 18.5 months versus 10.3 months with comparator.

GSK | 15/09/2026 | By News Bureau

GSK to Advance mRNA Seasonal Flu Vaccine Candidate to Phase 3

GSK advances its mRNA seasonal flu vaccine to phase 3 after positive phase 2 data showed higher immune responses versus standard and high-dose vaccines.

GSK | 02/09/2026 | By News Bureau

Jideytro Wins US Approval for ROS1-Positive NSCLC

Jideytro (zidesamtinib) has won US approval for previously treated ROS1-positive NSCLC, backed by ARROS-1 trial results showing durable responses.

GSK | 24/07/2026 | By News Bureau |  121

EMA Accepts Bexsero Label Update for Meningitis B Booster

The European Medicines Agency (EMA) has accepted a label update for Bexsero that could enable a single booster dose to protect individuals aged 10 years and older previously vaccinated against Meningitis B.

GSK | 21/07/2026 | By News Bureau |  122

GSK's Jemperli Shows Durable Complete Responses in Rectal CancerGSK's Jemperli (dostarlimab) achieved durable complete responses in dMMR/MSI-H locally adva

GSK's Jemperli (dostarlimab) achieved durable complete responses in dMMR/MSI-H locally advanced rectal cancer, with potential to avoid chemotherapy, radiation, and surgery in some patients.

GSK | 14/07/2026 | By News Bureau |  107

US FDA Approves Utebzi for Adult Patients with Complicated UTIs

The US Food and Drug Administration (FDA) has approved GSK’s Utebzi (tebipenem pivoxil) for adults with complicated Urinary Tract Infections (cUTIs), becoming the first and only oral carbapenem antibiotic available. The approval is based on the phase 3 PIVOT-PO trial, which demonstrated non-inferiority to standard intravenous antibiotic treatment.

GSK | 19/06/2026 | By News Bureau |  148

GSK Enters Agreement to Acquire Nuvalent

GSK has agreed to acquire Nuvalent in a multi-product oncology deal that strengthens its lung cancer portfolio with two late-stage, potential best-in-class therapies—zidesamtinib and neladalkib—for non-small cell lung cancer.

GSK | 10/06/2026 | By News Bureau |  278

GSK Reports Positive Phase 3 Results for Bepirovirsen in Chronic Hepatitis B Treatment

GSK’s investigational antisense oligonucleotide bepirovirsen demonstrated statistically significant functional cure rates in chronic hepatitis B patients, offering a potential alternative to lifelong antiviral therapy.

GSK | 29/05/2026 | By News Bureau |  318

GSK Partners with Sino Biopharmaceutical to Accelerate Hepatitis B Therapy Launch in China

GSK and Sino Biopharmaceutical’s CTTQ have partnered to accelerate the launch of bepirovirsen in China, aiming to expand access to a potential first-in-class chronic hepatitis B therapy with functional cure potential.

GSK | 12/05/2026 | By News Bureau |  139

Onco-Innovations Subsidiary Partners with GSK on Real-World Oncology Data Research

Inka Health and GSK will collaborate to develop real-world data methodologies aimed at improving the applicability of oncology clinical trial findings across diverse patient populations and healthcare settings.

GSK | 07/05/2026 | By News Bureau |  138